![20th Anniversary - Logos [RGB]_Growth](/media/131950/20th-anniversary-logos-rgb-_growth.png)
Research Partnership is UK’s fastest growing healthcare market research specialist
The latest league tables for the UK market research industry have just been released and reveal Research Partnership to be the fastest growing healthcare market research specialist for 2014.
The latest league tables for the UK market research industry have just been released and reveal Research Partnership to be the fastest growing healthcare market research specialist for 2014. Every year the Market Research Society (MRS) uses the turnover published by Companies’ House to produce its league tables.
Exploring the Opportunity For Halal In Healthcare
Published in Medical Marketing & Media November 2015
As pork is forbidden by Islam, the use of pork-based gelatin in many vaccines has resulted in considerable resistance to vaccination among the Islamic community. Data has demonstrated a decrease in immunization rates in majority Muslim countries such as Nigeria and Pakistan, where leaders and clerics have made complex claims against vaccines. A 2012 survey of parents in an Islamic primary school in Australia found that over 40% did not feel they knew enough about vaccines to make informed decisions, with over 70% expressing a desire for further information to reduce the uncertainty.
How the opportunity for a product treating a rare haematology disease in Emerging Markets was evaluated using a multi-stakeholder approach
Our client wanted to determine how to maximise the commercial opportunities for a product indicated for a rare disease in a range of emerging markets
Research Partnership recently conducted a study to determine how to maximise the commercial opportunities for a product indicated for a rare disease in a range of emerging markets. A three-phase methodology was utilised and gave the client in-depth insights into the specific opportunities and challenges as well as clear recommendations on the execution of strategy and tactical approach required to successfully maximise the product opportunity for each individual market.
12 Challenges Big Pharma Faces in China
Published in eyeforpharma 16 November by Rachel Howard
What challenges must pharma companies overcome in order to successfully leverage the opportunity China offers? For this month’s article, I asked my team of emerging market experts to share their thoughts. In 2004 Austin Lally, General Manager of Procter & Gamble’s beauty care business in China, famously declared there to be “no such thing as China – there are 1,000 Chinas, where consumers have differing aspirations and spending power. Marketers must grasp that complexity or fail”. Despite ongoing economic development across China, this holds as true today as it did back in 2004. It is also just as applicable to healthcare industry as it is in the consumer world. The opportunity for pharma in a level 3a hospital* in a coastal tier 1 city is unrecognizable from that in a rural polyclinic in a remote province in Western China. While the tier 1 cities of Beijing, Shanghai and Guangzhou have much in common with developed economies, ‘emerging’ tier 2 and 3 cities represent the country’s key growth drivers – they are therefore increasingly relevant for pharma to understand.
From promise to practice: immuno-oncology in action
Our latest Free Thinking white paper series explores what the global outlook is like for new immunotherapy products and asks key opinion leaders and payers how they’re faring both clinically and financially
Immuno-oncology therapies that harness the body's own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment.
Clinical trials of emerging products, both alone and in combination, have delivered impressive evidence of improvements in durability and endpoints such as progression-free survival, and even overall survival. R&D pipelines are stuffed with immuno-oncology prospects across a wide range of indications.
To date, only a few immuno-oncology products have actually reached the market though. Two of them target the anti-PD1/PD-L1 pathway where much of the interest in immuno-oncology is currently invested.
We spoke to key opinion leaders and payers in the US and EU to find out how the new immunotherapy products are faring clinically and financially.